Careers  |  Sign In  |  Register  |   Twitter

Aflibercept Approved for Colon Cancer Treatment

The FDA has approved aflibercept (Zaltrap, Sanofi & Regeneron) as a second-round treatment for metastatic colorectal cancer (mCRC) in addition to the FOLFIRI (leucovorin calcium, fluorouracil, irinotecan hydrochloride) chemotherapy regimen. Aflibercept is a dual inhibitor of VEGF-A and PIGF, both proteins that promote angiogenesis that aid in tumor growth and proliferation. Based on the phase III VELOUR trial, Aflibercept was shown to increase overall survival by 1.4 months when used with FOLFIRI as opposed to just treating with FOLFIRI. Aflibercept was already approved for age-related macular degeneration, and the companies hope to expand it into further cancer treatment.

Read it in OncLive.